OCT-1 activity and molecular response
| . | Achieved MMR (% of n) . | Did not achieve MMR (% of n) . |
|---|---|---|
| MNC (P = .017) | ||
| High OA (n = 9) | 9 (100%) | 0 (0%) |
| Low OA (n = 25) | 14 (56%) | 11 (44%) |
| CD34+ (P = .026) | ||
| High OA (n = 17) | 8 (47%) | 9 (53%) |
| Low OA (n = 17) | 15 (88%) | 2 (12%) |
| . | Achieved MMR (% of n) . | Did not achieve MMR (% of n) . |
|---|---|---|
| MNC (P = .017) | ||
| High OA (n = 9) | 9 (100%) | 0 (0%) |
| Low OA (n = 25) | 14 (56%) | 11 (44%) |
| CD34+ (P = .026) | ||
| High OA (n = 17) | 8 (47%) | 9 (53%) |
| Low OA (n = 17) | 15 (88%) | 2 (12%) |
Shown are the number of patients who did and did not achieve a major molecular response (MMR) over the first 12 months of imatinib therapy. P values were calculated using the Fisher Exact test.